The Impact and Treatment of COVID-19 in Hemodialysis Patients

Background: Patients with coronavirus disease 2019 (COVID-19) undergoing maintenance hemodialysis have a poor prognosis and limited treatment options. Methods: This paper outlines the impact of COVID-19, its treatment, and the efficacy of vaccines in Japanese patients undergoing hemodialysis with a review of the literature. Results: Patients undergoing dialysis in dialysis facilities are at greater risk of exposure to severe acute respiratory syndrome coronavirus 2 than the general population due to limited isolation capabilities. Therefore, vaccines are expected to be effective for patients undergoing dialysis. In addition, effective use of available medications is important because treatment options are limited. Conclusions: Efforts should be made to prevent the spread of the infection to high-risk patients undergoing dialysis while ensuring the effective use of vaccines.

[1]  Macide Artac Ozdal,et al.  Risk of COVID-19 and Cost Burden in End-Stage Renal Disease Patients and Policy Implications for Managing Nephrology Services during the COVID-19 Pandemic , 2022, Healthcare.

[2]  K. Kikuchi,et al.  Implementation of two novel schemes for patients on dialysis as a response to the COVID-19 surge in Tokyo. , 2022, Global health & medicine.

[3]  D. Kamińska,et al.  Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients , 2022, Viruses.

[4]  M. Cozzolino,et al.  Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy , 2022, Vaccines.

[5]  N. Babel,et al.  Vaccination in patients with kidney failure: lessons from COVID-19 , 2022, Nature Reviews Nephrology.

[6]  J. Sim,et al.  Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19 , 2022, Clinical kidney journal.

[7]  H. van Bakel,et al.  Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.

[8]  A. Salama,et al.  Severity of COVID-19 after Vaccination among Hemodialysis Patients , 2022, Clinical journal of the American Society of Nephrology : CJASN.

[9]  M. Nangaku,et al.  Effectiveness of SARS‐CoV‐2 vaccines on hemodialysis patients in Japan: A nationwide cohort study , 2022, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[10]  D. Katagiri.  For safe and adequate blood purification therapy in severe COVID-19 ‒ what we have learned so far. , 2022, Global health & medicine.

[11]  J. Goss,et al.  COVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant Recipients , 2022, Current Transplantation Reports.

[12]  S. Voidăzan,et al.  Negative Impact of the COVID-19 Pandemic on Kidney Disease Management—A Single-Center Experience in Romania , 2022, Journal of clinical medicine.

[13]  J. Wetmore,et al.  COVID-19 and kidney disease: insights from epidemiology to inform clinical practice , 2022, Nature Reviews Nephrology.

[14]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[15]  F. Tentori,et al.  Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector–Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients , 2022, Journal of the American Society of Nephrology : JASN.

[16]  D. Katagiri,et al.  Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan , 2022, CEN Case Reports.

[17]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[18]  M. Nangaku,et al.  Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study , 2021, Renal Replacement Therapy.

[19]  M. Hladunewich,et al.  COVID-19 Vaccination Imperatives in People on Maintenance Dialysis. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[20]  J. Perl,et al.  COVID-19 Among Adults Receiving Home Versus In-Center Dialysis. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[21]  M. Nangaku,et al.  Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey , 2021, Renal Replacement Therapy.

[22]  A. Kimura,et al.  Direct hemoperfusion using a polymyxin B‐immobilized polystyrene column for COVID‐19 , 2020, Journal of clinical apheresis.

[23]  W. Sugiura,et al.  Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Sugiyama,et al.  Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers , 2020, Critical care explorations.

[25]  M. Nangaku,et al.  COVID‐19 of dialysis patients in Japan: Current status and guidance on preventive measures , 2020, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.